Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $187.41 USD
Change Today +3.51 / 1.91%
Volume 2.2M
ILMN On Other Exchanges
As of 8:10 PM 12/1/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5200 Illumina Way

San Diego, CA 92122

United States

Phone: 858-202-4500

Fax: 858-202-4766

fic genes, or other genomic regions of interest. The company’s sequencing kits improve the ability of its customers to characterize the target genome accurately. Through its acquisition of Epicentre Technologies Corporation, the company owns the proprietary Nextera technology for next-generation sequencing library preparation. This technology has enabled the company to reduce sample input requirements, simplify genetic analysis workflows, and reduce the time from sample preparation to answer. Customers use the company’s array-based genotyping consumables for a range of analyses, including various species, disease-related mutations, and genetic characteristics associated with cancer. Customers could select from a range of human, animal, and agriculturally relevant genome panels or create their own custom arrays to investigate approximately 5,000,000 genetic markers targeting any species. Services In addition to selling products, the company provides genotyping, NIPT, and whole-genome sequencing services. Human whole-genome sequencing services are provided through its Clinical Laboratory Improvements Amendments-certified, the College of Pathologists-accredited laboratory. The company offers genotyping and sequencing services to academic institutions, biotechnology, and pharmaceutical customers. Using its FastTrack services, customers could perform whole-genome sequencing projects (including phasing and long-read sequencing services) and microarray projects (including large-scale genotyping studies and whole-genome association studies). The company also provides NIPT services through its partner laboratories that direct samples to the company on a test send-out basis. Customers The company’s customers include major genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. Principal Markets The company serves life sciences, reproductive and genetic health, oncology, enterprise informatics, and new and emerging markets. Marketing and Distribution The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region. In each of these areas, dedicated sales, service, and application-support personnel are expanding and supporting their respective customer bases. In addition, it sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and South Africa. Sales The company has sales offices located internationally throughout Europe, the Asia-Pacific region, and Brazil. Acquisitions In 2014, the company acquired Myraqa, Inc. Its acquisition of Myraqa, Inc. bolstered the company’s regulatory and quality capabilities and improved its leadership team in molecular and companion diagnostics. Intellectual Property As of February 1, 2015, the company owned or had exclusive licenses to 473 issued U.S. patents and 421 pending U.S. patent applications, including 19 allowed applications that have not yet issued as patents. Its issued patents cover various aspects of its arrays, assays, oligo synthesis, sequencing technology, instruments, digital microfluidics, and chemical-detection technologies; and have terms that expire between 2015 and 2035. The company has filed or has been granted counterparts for majority of these patents and applications in foreign countries. Research and Development The company’s research and development expenses were $388.1 million for the year ended December 28, 2014. Intellectual Property Illumina, BaseSpace, BeadArray, BlueGnome, cBot, CSPro, DASL, DesignStudio, Epicentre, ForenSeq, Genetic Energy, GenomeStudio, GoldenGate, HiScan, HiSeq, HiSeq X, Infinium, iScan, iSelect, MiSeq, MiSeqDx, MiSeq FGx, NeoPrep, NextBio, Nextera, NextSeq, SeqMonitor, TruGenome, TruSeq, TruSight, Understand Your Genome, UYG, VeraCode, verifi, VeriSeq, the pumpkin orange color, and the Genetic Energy streaming bases design are certain of the company’s trademarks. C


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILMN:US $187.41 USD +3.51

ILMN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $41.06 USD -0.76
Dr Reddy's Laboratories Ltd 3,252 INR +40.60
Symrise AG €62.69 EUR -1.33
Waters Corp $133.38 USD +0.56
View Industry Companies

Industry Analysis


Industry Average

Valuation ILMN Industry Range
Price/Earnings 53.7x
Price/Sales 12.5x
Price/Book 13.9x
Price/Cash Flow 48.4x
TEV/Sales 11.4x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ILLUMINA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at